Look to the future in eye care

See IPAC

Bringing innovation to China, Japan, Korea, and the Asia-Pacific region

IPAC Pharmaceuticals is an innovative ophthalmic company developing a portfolio of novel assets for the Asia-Pacific region, beginning with ocular pain and dry eye disease

A new era in ophthalmology

Due to an emerging gap between small research firms and large pharmaceutical companies, research ideas with great potential have limited opportunities for development. IPAC is filling this gap to accelerate innovation, address unmet need, and advance the eye care industry.

Dedicated and experienced team

IPAC’s leadership brings extensive experience with a history of success in ophthalmology, R&D execution, and pharmaceutical startups. Our team is dedicated to bringing the best ophthalmic innovations to market.

Emerging innovative technologies

We identify ground-breaking technologies that will make a difference in patients’ lives and launch them into effective eye care products.

Innovative eyecare

IPAC Pharmaceuticals is an R&D focused company that is creating innovative treatment-opportunities in the ever-growing industry of ophthalmology and eye care.

For early stage companies, we are a dramatic pharmaceutical accelerator partner. For clinic-ready ophthalmology programs, we can perform clinical studies faster, cheaper, and with the potential for go to market partnering opportunities for the Asia-Pacific region.

We are now well-positioned to accelerate the development of IC 265 and IC 270 for approval in China and other markets in Southeast Asia. The efficacy of IC 265 and IC 270 is supported by significant clinical data and it is a natural fit for our robust product development strategy

DR. BENJAMIN LI

CHAIRMAN OF ZKO

Treating therapeutic areas in

OPHTHALMOLOGY

Targeting two therapeutic areas

Dry eye and ocular pain are two large therapeutic areas with significant unmet need

Filling the gap in the pipeline

Major pharmaceutical companies have created a large gap in the market as they significantly reduced their internal R&D efforts

Significant market potential

The global eye care market size is growing due to aging population, increased screen use, and climate change

Industry experienced

LEADERSHIP

Ophthalmology is a niche therapeutic area that requires specific expertise

IPAC is led by former top executives from the leading eye care companies in the world. With their collective knowledge of global R&D operations, formulation development, and regulatory, they are driving IPAC to success.

DAMON BURROWS

CO-FOUNDER & CHIEF EXECUTIVE OFFICER

GEORGE NG

CO-FOUNDER & CHIEF BUSINESS OFFICER

YOGESH BAHL

CHIEF FINANCIAL OFFICER

EDWIN WONG

ADVISOR

XIAOFENG “JOHN” XU

COMMERCIAL ADVISOR

Our business partnerships

We’re partnering with the best in the pharmaceutical industry to bring patients effective and innovative eye care products

Cutting-edge and innovative

R&D

Enhanced delivery to ocular tissues

New technologies including nano-encapsulation are providing a breakthrough in the ability to deliver drugs to the eye

CEO Damon Burrows was featured on the OIS Podcast.

Listen to the podcast to learn more about IPAC’s CEO Damon Burrows and his career path that lead him to starting IACTA Pharmaceuticals and IPAC Pharmaceuticals. Damon also talks about the IC 265 platform and what makes it a tolerable anti-inflammatory.

Let’s get

Connected

The team at IPAC understands that building a pharmaceutical company is more than science and technology. We need people like you!

We would love to hear from you if you have interest in areas of clinical development to commercial.